Solid-pseudopapillary neoplasms (SPNs) are rare, accounting for 1% to 2% of all exocrine pancreatic tumors. Approximately 90% of SPNs occur in young women, with an average age of diagnosis at 35 years. SPNs are considered malignant neoplasms with an indolent disease course. Most patients have a solitary lesion without metastatic disease, and surgical resection is curative with more than 95% survival at 5 years. However, metastatic disease does occur in 5% to 15% of cases, and is usually present at the time of initial diagnosis.
Conclusions: Both SOX11 and TFE3 were overexpressed in SPNs and may be involved in the pathogenesis. Clinically, SOX11 and TFE3 can be potentially used as diagnostic markers in distinguishing indeterminate SPNs from their histologic mimickers.
Solid-pseudopapillary neoplasms (SPNs) are rare, accounting for 1% to 2% of all exocrine pancreatic tumors. Approximately 90% of SPNs occur in young women, with an average age of diagnosis at 35 years. SPNs are considered malignant neoplasms with an indolent disease course. Most patients have a solitary lesion without metastatic disease, and surgical resection is curative with more than 95% survival at 5 years. However, metastatic disease does occur in 5% to 15% of cases, and is usually present at the time of initial diagnosis. 1 SPNs may occur anywhere in the pancreas. The tumor cells are arranged in sheets, cords, and nests separated by a fine vascular network. 1, 2 Loss of membranous E-cadherin, combined with the degeneration of the tumor cells due to outgrowing the blood supply, gives SPN its classic discohesive pseudopapillary architecture. 3 Morphological variants, such as clear cell variant, have been reported, which makes the histologic diagnosis more challenging. 4 The exact pathogenesis of SPNs remains unknown. Sequencing studies indicate that SPNs contain few genetic alterations compared with other types of pancreatic tumors, but on the other hand, more than 90% of SPNs carry a somatic mutation in exon 3 of the CTNNB1 gene, which encodes β-catenin.
5-8 β-catenin is responsible for cell-to-cell adhesions and regulating gene transcription through the Wnt signaling pathway. In normal cells, the absence of Wnt signaling leads to β-catenin being phosphorylated by glycogen synthase 3 (GSK3) resulting in the formation of a "destruction complex" containing a cocktail of proteins such as Axin1, adenomatous polyposis coli, casein kinase 1α, and GSK3. This ultimately leads to ubiquitination and proteosomal degradation of β-catenin. Inversely, in the presence of Wnt signaling, GSK3 and Axin1 are sequestered inside late endosomes, which then allow β-catenin to accumulate in the cytosol and ultimately translocate to the nucleus to regulate the transcription of various genes through formation of a β-catenin-T-cell factor (TCF) complex. 9, 10 In SPN, there is a gain of function mutation in the β-catenin gene, which prevents it from being ubiquitinated and degraded by proteasomes. This leads to cytoplasmic and nuclear accumulation of β-catenin, which gives SPN its characteristic strong cytoplasmic and nuclear immunoreactivity for β-catenin.
5
Many transcription factors and regulators interact with the Wnt/β-catenin signaling pathway. SOX (SRYrelated HMG-box) proteins are transcriptional regulators involved in diverse tissues and developmental processes. The mammalian SOX family consists of 20 proteins that are functionally categorized into nine subgroups.
11
This family is responsible for regulating lineage and tissue-specific gene expression patterns through modulation of several processes, including cell differentiation, sex determination, and development of the central nervous, hematopoietic, and other organ systems. 11, 12 SOX genes are frequently deregulated in different tumor types and act as a tumor suppressor or oncogene. [11] [12] [13] It has been shown that SOX proteins are key modulators of the Wnt/β-catenin signaling pathway, bind directly to β-catenin or TCF, and prevent interaction between β-catenin and TCF.
13 SOX15, SOX7, SOX17, SOX6, and SOX9 can suppress Wnt/β-catenin signaling in various types of malignant tumors. [14] [15] [16] The interaction between SOX11 and Wnt/β-catenin signaling has never been reported. Interestingly, recent RNA microarray and gene regulatory network analyses revealed that SOX11 mRNA consistently increased in SPNs when compared with normal pancreas and pancreatic neuroendocrine tumors. 17 The microphthalmia family of transcription factors (MiT) is composed of four factors: MITF, TFEB, TFE3, and TFEC. These factors are considered oncogenes and have been shown to be amplified in several malignancies, including melanoma, pediatric renal cell carcinoma, and alveolar soft part sarcoma. MITF overexpression has been associated with enhanced Wnt signaling by increasing the sequestration of destruction complex proteins such as Axin1 and GSK3. 9 Transcription factor E3 (TFE3) is involved with the biogenesis of lysosomes and autophagosomes, as well as the clearance of cellular debris.
9 TFE3 is also associated with the ASPL-TFE3 gene fusion in alveolar soft part sarcoma. 18 It is possible that overexpression of other members of the MiT family, such as TFE3, could also be related to the Wnt/β-catenin signaling pathway. To date, whether TFE3 is overexpressed in SPNs remains unknown.
In this study, we analyzed the SOX11 and TFE3 protein expression by immunohistochemistry in a relatively large cohort of SPNs, as well as other pancreatic tumors that histologically mimic SPN.
Material and Methods
This study was approved by the Duke University institutional review board. The Duke pathology database was searched from 2000 to 2015, and 31 cases of resected SPN were retrieved. In addition, 31 cases of other pancreatic tumors, including two consecutive acinar cell carcinomas, three consecutive pancreatoblastomas, and 26 randomly selected neuroendocrine tumors (grade 1 or 2), were used as controls. The H&E-stained sections from each case were reviewed by a pathologist and a block was chosen for immunohistochemistry. Each case was subsequently stained with TFE3, SOX11, and β-catenin. The TFE3, SOX11, and β-catenin immunohistochemical stains were scored independently by at least two pathologists in a masked manner. Fluorescence in situ hybridization (FISH) analysis for TFE3 gene rearrangement was performed on 17 randomly selected SPN cases. In addition, demographic information was collected from the patients' medical record, including current age, age of diagnosis, sex, presence of metastatic disease, and mortality status.
All immunohistochemistry was performed on a Leica Biosystems Bond III automated stainer (Buffalo Grove, IL) using 5-µm thick, formalin-fixed, paraffin-embedded tissue sections mounted on positively charged slides. Heatinduced antigen retrieval was performed using Epitope Retrieval Solution 2 (Leica Biosystems) for 20 minutes. The details for immunohistochemistry are summarized in ❚Table 1❚. For TFE3, a monoclonal rabbit anti-TFE3 antibody against the C-terminal portion of the TFE3 protein was used (Cell Marque, Catalog No. 354R-15, Rocklin, CA; 1:75 dilution, incubated for 30 minutes at room temperature). A Novocastra Refine Detection Kit (Leica Biosystems) was used for antigen detection, which contains a 3,3'-diaminobenzidine tetrahydrochloride chromogen. For SOX11, the antigen detection was performed using a monoclonal mouse anti-SOX11 antibody (Cell Marque, Catalog No. PA0816; predilution concentration, incubated for 15 minutes at room temperature). After binding of the primary antibody, Bond Refine HRP Detection (Leica Biosystems) was used for antigen detection. The Bond Refine HRP Detection kit is a biotin-free, polymeric TFE3 and SOX11 nuclear immunoreactivity was scored from 0 to 3+ as described by Argani et al. 18 Briefly, tumors showing nuclear staining that was readily apparent at low-power magnification (2×-4× objective) were scored as strongly positive (3+), and those showing nuclear staining that was readily apparent at intermediate magnification (10× objectives) were scored as moderately positive (2+). The tumors that showed weak nuclear staining, which was only apparent at high magnification (20×-40× objectives), were scored as weakly positive (1+). Cytoplasmic staining was ignored. The H-score was further calculated using the following formula: [1 × (% of cells with 1+ immunoreactivity) + 2 × (% of cells with 2+ immunoreactivity) + 3 × (% of cells with 3+ immunoreactivity)].
β-catenin immunoreactivity was scored as either positive or negative. Positive immunoreactivity for β-catenin was demonstrated as strong nuclear and cytoplasmic positivity. Tumors with cytoplasmic/membranous staining in the absence of nuclear immunoreactivity were considered negative.
FISH analysis for TFE3 gene rearrangement was performed on 5-µm thick, formalin-fixed, paraffin-embedded sections of the tumor using a break-apart probe flanking the genomic regions of TFE3 (Empire Genomics, Catalog No. TFE3BA-20-ORGR, Buffalo, NY). The TFE3 probe set hybridizes to the Xp11.2 band on the 5' telomeric side and 3' centromeric side of the TFE3 locus breakpoints. Signals were considered to be split when the green and orange signals were separated by a distance of greater than two signal diameters. A minimum of 100 tumor cell nuclei were examined with only nonoverlapping tumor nuclei evaluated. The normal cutoff for TFE3 rearrangement in males is less than 20% and in females less than 12%. A centromere X chromosome control probe (Spectrum Aqua, Abbott Molecular, Abbott Park, IL) was also used. Controls were reviewed and performed appropriately.
Results
Thirty-one resected SPNs were retrieved from the pathology archives. Of the patients with a diagnosis of SPN, five were males (16%) and 26 were females (84%). The average age at diagnosis was 35 years (range, 11-76 years). Only one patient had evidence of metastatic disease at the time of diagnosis, which was to the liver. Only one patient is known to be dead, and the cause of death was related to complications of surgery, comorbidities, and advanced age. All SPN cases showed both nuclear and cytoplasmic expression of β-catenin. Four control tumors showed nuclear expression of β-catenin (two neuroendocrine tumors and two pancreatoblastomas). Both pancreatoblastomas showed diffuse nuclear immunoreactivity for β-catenin. One additional pancreatoblastoma with focal immunoreactivity localized in squamoid corpuscles was graded as negative.
Nonneoplastic pancreatic tissue exhibited variable cytoplasmic staining for SOX11. In 98% (46/47) of sampled pancreas, the acinar cells showed cytoplasmic staining (92% moderate to strong, 6% weak). The ducts and islets showed relatively weak cytoplasmic staining in 81% (38% moderate, 43% weak) and 91% (51% moderate, 40% weak) of the cases, respectively. No nuclear immunoreactivity was present in nonneoplastic pancreatic tissue. Nuclear immunoreactivity for SOX11 was detected in all SPNs and five (16%) of the 31 control tumors (four neuroendocrine tumors and one pancreatoblastoma), resulting in a sensitivity of 100%, specificity of 84%, negative predictive value (NPV) of 100%, and positive predictive value (PPV) of 86% ❚Table 2❚ and ❚Image 1❚. Three (10%) of the SPNs showed weak nuclear immunoreactivity (1+), 15 (48%) showed moderate nuclear immunoreactivity (2+), and 13 (42%) showed strong nuclear immunoreactivity (3+) for SOX11. Most SPNs exhibited diffuse immunoreactivity for SOX11, with H-scores ranging from 50 to 300 (median, 230; average, 218). All five false-positive control tumors exhibited patchy weak immunoreactivity (1+) for SOX11, with H-scores ranging from 15 to 40. It is worth mentioning that several neuroendocrine tumors showed rare individual cells with strong nuclear immunoreactivity for SOX11, which gave rise to an H-score of less than 3 (less than 1% of 3+ cells). Such a pattern was not observed in any SPN cases. These positive cells in neuroendocrine tumors likely represent inflammatory cells instead of tumor cells. Therefore, these cases were considered negative in this study (Image 1). Nonneoplastic pancreatic tissue was consistently negative for TFE3. Nuclear immunoreactivity for TFE3 was detected in 30 of the 31 (97%) SPNs and three of the 31 (10%) control tumors (three neuroendocrine tumors), resulting in a sensitivity of 97%, specificity of 90%, NPV of 97%, and PPV of 91% (Table 2, Image 1). Among the SPNs positive for TFE3, 12 (40%) cases showed weak nuclear immunoreactivity (1+), 17 (57%) showed moderate nuclear immunoreactivity (2+), and one (3%) showed strong nuclear immunoreactivity (3+) for TFE3. SPNs showed more diffuse positivity for TFE3, with H-scores ranging from 10 to 280 (median, 130; average, 120). The three false-positive control tumors all demonstrated patchy weak nuclear immunoreactivity for TFE3 (1+, H-scores 5 to 10). In addition, 17 SPN cases were evaluated for the TFE3 gene rearrangement by FISH, and all were negative. These included one case with 3+ immunoreactivity, 10 cases with 2+ immunoreactivity, five cases with 1+ immunoreactivity, and one negative case.
Overall five neuroendocrine tumors and two pancreatoblastomas showed false positivity for various markers ❚Image 2❚. Among these, two neuroendocrine tumors and one pancreatoblastoma were positive for one marker; two neuroendocrine tumors and one pancreatoblastoma were positive for two markers; and one neuroendocrine tumor was positive for all three markers ❚Table 3❚. In order to achieve the optimal diagnostic value, we combined β-catenin, TFE3, and SOX11 as panels. When tumors with nuclear immunoreactivity to both β-catenin and SOX11 were considered positive, the results showed a sensitivity of 100%, specificity of 94%, NPV of 100%, and PPV of 94%. When tumors with nuclear immunoreactivity to all 3 markers were considered positive, the specificity was increased to 97%, with a slightly compromised sensitivity of 97% (NPV of 97%, PPV of 97%, Table 2 ).
Discussion
SPN is an enigmatic tumor with unclear cell of origin and direction of differentiation. Recent studies suggest that aberrant Wnt/β-catenin signaling may be a driver of tumorigenesis, since relatively few genetic alterations were detected in SPNs when compared with other types of pancreatic tumors, whereas more than 90% of SPNs harbor gain-of-function mutations in CTNNB1 gene. [5] [6] [7] [8] However, gene expression studies at mRNA level revealed much larger numbers of genes and signaling pathways that were differentially expressed in SPN, indicating more complicated underlying molecular mechanisms for the pathogenesis of SPN. 17, 19 In this study, we demonstrated that SOX11 (a transcription regulator) and TFE3 (a transcription factor) were overexpressed in SPNs and may be involved in the pathogenesis of this rare tumor.
SOX11 is widely expressed during embryogenesis, including the development of fetal pancreas, but absent in Recently, Li et al 17 used gene regulatory network analysis to identify new candidate genes that had the shortest paths from 26 known SPN-related genes, including CTNNB1, TCF/lymphoid enhancer-binding factor 1 (LEF1), CTNND1, and CDH1. The results showed that SOX11 mRNA was significantly upregulated in SPN (5.62-fold vs normal pancreas, 5.02-fold vs pancreatic neuroendocrine tumor). 17 Furthermore, Cho et al 22 reported SOX11 nuclear immunoreactivity in 28 of 34 SPN cases (82%), but this study was only published as an abstract. The exact biological function of SOX11 in SPN remains unknown. Since several other SOX factors modulate cell signaling pathways through binding directly to molecules such as β-catenin and TCF, 13 it is possible that SOX11 plays a regulatory role in SPN by directly binding other transcription factors via the SOX-HMG signature amino acid sequence-the defining structure for SOX proteins to mediate binding to DNA consensus motifs. Such a hypothesis is supported by an observation that SOX11 directly collaborates with cyclin D1 in early pathogenesis of mantle cell lymphoma. 21 TFE3 expression had been reported in various types of tumors, with the most useful applications in alveolar soft part sarcoma and Xp11 translocation renal cell carcinoma, but there is very limited evaluation of TFE3 in SPN. Argani et al 18 reported immunohistochemical studies of TFE3 in 68 different tumor types (1,476 total tumor cases). Eight of these tumor cases were SPNs, and none showed any nuclear immunoreactivity for TFE3. It is noted that different antibodies were used in their study and the current one. In their study, a polyclonal goat anti-TFE3 antibody was used; in contrast, we utilized a monoclonal rabbit anti-TFE3 antibody. Though both antibodies recognize the C-terminal portion of the TFE3 protein, subtle difference in targeted epitopes can cause performance variability. 23 Furthermore, Argani et al did not specify whether tissue microarrays or whole sections were used for the SPN cases in their study. 18 We used whole sections for immunohistochemistry in the current study. Theoretically, tissue microarrays may give rise to false negativity in some cases. To date, the mechanisms of TFE3 expression in SPN remains unknown. In contrast to TFE3 gene rearrangement in alveolar soft part sarcoma and Xp11 translocation renal cell carcinoma, our data showed no TFE3 gene rearrangement in SPN. The close association of other MiT family proteins in the Wnt signaling pathway may highlight a plausible cause of its overexpression.
Our data also indicate that SOX11 and TFE3 may be used as novel diagnostic markers when SPN is in the differential diagnosis of a pancreatic tumor. The diagnosis of SPN often relies on the integration of clinical, morphological, and immunohistochemical studies. Historically, β-catenin immunohistochemistry has been the most useful marker for distinguishing SPN from its most common morphological mimickers, particularly neuroendocrine tumors. In normal pancreatic acinar cells, β-catenin is localized to the cell membrane. Because of aberrant Wnt/β-catenin signaling, nuclear β-catenin immunoreactivity is characteristic of SPN. However, other pancreatic tumors, including acinar cell carcinoma, neuroendocrine tumor, and pancreatoblastoma, may share similar morphological features and also exhibit nuclear immunoreactivity for β-catenin (acinar cell carcinoma 12%, neuroendocrine tumor 8%). 24, 25 Differentiating pancreatic SPN from these mimickers can be challenging in selected cases, particularly when there is nuclear immunoreactivity for β-catenin in neuroendocrine tumors or synaptophysin/chromogranin A immunoreactivity in SPNs. It has been reported that the loss of E-cadherin in SPN might be diagnostically helpful, but one of these studies was limited by only six cases of SPN, 25 and the specificity was not well-characterized in the other study. 26 TCF/ LEF1 has been shown to be a highly sensitive and specific marker in distinguishing SPN from pancreatic neuroendocrine tumor and acinar cell carcinoma, but it is also positive in pancreatoblastomas, although in a less diffuse pattern. 26 In our study, SOX11 showed a sensitivity of 100% and specificity of 84%. Four neuroendocrine tumors and one pancreatoblastoma showed focal weak nuclear positivity for SOX11, and none of the control tumors showed strong immunoreactivity. The H-scores had no overlap between SPNs (50-300) and false-positive control tumors . Therefore, diffuse or moderate to strong (2+ to 3+) positivity for SOX11 is very specific for SPN. A potential pitfall for interpretation is that rare individual cells (possible inflammatory cells) may show immunoreactivity for SOX11. Such a pattern was not observed in any SPN cases and should be interpreted as negative.
TFE3 immunoreactivity in SPN resulted in a sensitivity of 97% and specificity of 90%. The staining intensity was predominately weak to moderately intense, with 29 (97%) tumors showing 1+ to 2+ nuclear staining intensity, and only one showing strong (3+) immunoreactivity. This is in keeping with the notion that different mechanisms are involved in SPNs and other TFE3-overexpressing tumors because alveolar soft part sarcomas usually exhibit strong immunoreactivity for TFE3. Fortunately, immunohistochemistry for TFE3 performed in our laboratory showed minimal background staining, which made crisp nuclear staining readily appreciable. The three false-positive control tumors all demonstrated weak nuclear immunoreactivity for TFE3 (1+, H-score of 5, 5, and 10). In SPNs that were positive for TFE3, only one case had an H-score of 10. Therefore, diffuse or moderate to strong (2+ to 3+) nuclear staining is also specific for SPN.
In this series, all 31 SPNs expressed strong nuclear and cytoplasmic immunoreactivity for β-catenin, resulting in a sensitivity of 100% and specificity of 87%, similar to those reported in the literature. 24, 25 The diagnostic value can be further optimized by combining the markers as panels. When β-catenin and SOX-11 were used as a panel and immunoreactivity for both SOX11 and β-catenin was defined as positive, the sensitivity remains 100% with the specificity increased to 94%. When all three markers were combined and immunoreactivity to all three markers was considered positive, the specificity was increased to 97%, with a slightly compromised sensitivity of 97%.
In conclusion, we have profiled 31 cases of SPN, and demonstrated that SOX11 and TFE3 were overexpressed. Although the molecular mechanisms of their overexpression remain unclear, our data suggest further investigation on the roles of SOX11 and TFE3 in the pathogenesis of SPN. Furthermore, we propose that SOX11 and TFE3 can be used as potential diagnostic markers for SPN. The combinations of β-catenin, TFE3, and SOX11 as immunohistochemical panels result in the optimal sensitivity and specificity. Including SOX11 and TFE3 in the immunohistochemical panel may be of value in distinguishing indeterminate SPN from other pancreatic tumors in clinical practice.
